APA
AVIR icon

American Portfolios Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

American Portfolios Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$722 – 3534
2022
Q1 		$722 Hold
100
– – ﹤0.01% 3421
2021
Q4 		$894 Hold
100
– – ﹤0.01% 3339
2021
Q3 		$3.51K Hold
100
– – ﹤0.01% 2981
2021
Q2 		$2.15K Hold
100
– – ﹤0.01% 3132
2021
Q1 		$6.17K Sell
100
-105
-51% -$7.09K ﹤0.01% 2615
2020
Q4 		$8.56K Buy
+205
New +$6.61K ﹤0.01% 2177

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

American Portfolios Advisors's AVIR Position: Q2 2022 in Review

American Portfolios Advisors sold out of Atea Pharmaceuticals (AVIR) in Q2 2022, closing a stake of 100 shares — an estimated $722 sold.

American Portfolios Advisors first reported a position in AVIR in Q4 2020 and held it in 6 quarters. The position peaked at $8.56K in Q4 2020. 127 funds tracked by Wall St. Rank hold AVIR as of Q2 2022.

  • American Portfolios Advisors reported no remaining Atea Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • American Portfolios Advisors sold 100 Atea Pharmaceuticals shares in Q2 2022, an estimated $722.
  • American Portfolios Advisors first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • American Portfolios Advisors's Atea Pharmaceuticals position peaked at $8.56K in Q4 2020.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2022.

Based on American Portfolios Advisors's 13F filing for Q2 2022, filed 20 Mar 2023.